Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Gamida publishes results of trial to evaluate omidubicel for stem cell treatment » 07:06
06/23/21
06/23
07:06
06/23/21
07:06
GMDA

Gamida Cell

$6.05 /

-0.01 (-0.17%)

Gamida Cell announced…

Gamida Cell announced that the results of a Phase 3 clinical study of omidubicel have been published in Blood, the official journal of the American Society of Hematology. Omidubicel is an advanced cell therapy under development as a potential life-saving allogeneic hematopoietic stem cell transplant solution for patients with hematologic malignancies. The results demonstrate that transplantation with omidubicel leads to faster neutrophil and platelet recovery compared to a standard umbilical cord blood graft, and results in fewer early bacterial and viral infections and less time in the hospital. "We are pleased that the data from this well-conducted international Phase 3 trial have been published in Blood, the highly respected, peer-reviewed journal of the American Society of Hematology," said Ronit Simantov,

ShowHide Related Items >><<
GMDA Gamida Cell
$6.05 /

-0.01 (-0.17%)

GMDA Gamida Cell
$6.05 /

-0.01 (-0.17%)

05/11/21 Oppenheimer
Gamida Cell progressing toward omidubicel BLA, says Oppenheimer
05/11/21 JMP Securities
JMP Securities bullish on Gamida Cell, says regulatory preparedness on track
03/09/21 Piper Sandler
Gamida Cell price target lowered to $23 from $25 at Piper Sandler
02/10/21 H.C. Wainwright
Gamida Cell price target raised to $27 from $15 at H.C. Wainwright
GMDA Gamida Cell
$6.05 /

-0.01 (-0.17%)

GMDA Gamida Cell
$6.05 /

-0.01 (-0.17%)

GMDA Gamida Cell
$6.05 /

-0.01 (-0.17%)

Over a month ago
Recommendations
Gamida Cell progressing toward omidubicel BLA, says Oppenheimer » 20:27
05/11/21
05/11
20:27
05/11/21
20:27
GMDA

Gamida Cell

$6.83 /

+0.04 (+0.59%)

Oppenheimer analyst Mark…

Oppenheimer analyst Mark Breidenbach keeps his Outperform rating and $17 price target on Gamida Cell after its Q1 results. The analyst states that his follow-up conversations with the management suggest that the company is making progress toward completing omidubicel's BLA and still expects to file in Q4. The company has adequate cash to sustain operations into the second half of next year, Breidenbach adds.

ShowHide Related Items >><<
GMDA Gamida Cell
$6.83 /

+0.04 (+0.59%)

GMDA Gamida Cell
$6.83 /

+0.04 (+0.59%)

05/11/21 JMP Securities
JMP Securities bullish on Gamida Cell, says regulatory preparedness on track
03/09/21 Piper Sandler
Gamida Cell price target lowered to $23 from $25 at Piper Sandler
02/10/21 H.C. Wainwright
Gamida Cell price target raised to $27 from $15 at H.C. Wainwright
02/09/21 Piper Sandler
Gamida Cell price target raised to $25 from $13 at Piper Sandler
GMDA Gamida Cell
$6.83 /

+0.04 (+0.59%)

  • 19
    May
GMDA Gamida Cell
$6.83 /

+0.04 (+0.59%)

GMDA Gamida Cell
$6.83 /

+0.04 (+0.59%)

Recommendations
JMP Securities bullish on Gamida Cell, says regulatory preparedness on track » 11:15
05/11/21
05/11
11:15
05/11/21
11:15
GMDA

Gamida Cell

$6.72 /

-0.07 (-1.03%)

JMP Securities analyst…

JMP Securities analyst Jason Butler reiterates an Outperform rating on Gamida Cell, with a price target of $19, after the company reported Q1 earnings ahead of expectations on lower-than-expected operating expenses. The analyst also highlights solid execution toward key 2021 milestones with omidubicel BLA submission on track for Q4 2021 and GDA-201 IND submission still expected in the second half of 2021. Commercial manufacturing activities are advancing well, and continue to support a BLA submission in Q4 2021, as the company is completing manufacturing comparability with its commercial sites and clinical supply, he adds. Butler remains "enthusiastic" about the differentiated clinical benefits demonstrated by omidubicel in the Phase 2 and 3 trials, the unmet need that the candidate addresses, and its commercial potential.

ShowHide Related Items >><<
GMDA Gamida Cell
$6.72 /

-0.07 (-1.03%)

GMDA Gamida Cell
$6.72 /

-0.07 (-1.03%)

03/09/21 Piper Sandler
Gamida Cell price target lowered to $23 from $25 at Piper Sandler
02/10/21 H.C. Wainwright
Gamida Cell price target raised to $27 from $15 at H.C. Wainwright
02/09/21 Piper Sandler
Gamida Cell price target raised to $25 from $13 at Piper Sandler
12/14/20 Oppenheimer
Gamida Cell price target lowered to $17 from $20 at Oppenheimer
GMDA Gamida Cell
$6.72 /

-0.07 (-1.03%)

  • 19
    May
GMDA Gamida Cell
$6.72 /

-0.07 (-1.03%)

GMDA Gamida Cell
$6.72 /

-0.07 (-1.03%)

Earnings
Gamida Cell reports Q1EPS 34c, consensus (40c) » 07:05
05/11/21
05/11
07:05
05/11/21
07:05
GMDA

Gamida Cell

$6.75 /

-0.07 (-1.03%)

As of March 31, 2021,…

As of March 31, 2021, Gamida Cell had total cash and cash equivalents of $174.8 million, compared to $127.2 million as of December 31, 2020. "In the first quarter of this year, we made significant progress on key initiatives across all functions of our business, starting with omidubicel, a potentially transformative treatment option for patients with hematological malignancies," said Julian Adams, Ph.D., chief executive officer of Gamida Cell. "We are working diligently to bring this novel therapy to patients, with submission of a BLA to the FDA anticipated in the fourth quarter of this year. We are progressing well with our manufacturing readiness activities in response to the clear feedback from the FDA regarding registration of our commercial manufacturing facilities and are actively building our launch readiness capabilities, including market access and support services, to ensure a positive patient experience at transplant at the time of potential FDA approval."

ShowHide Related Items >><<
GMDA Gamida Cell
$6.75 /

-0.07 (-1.03%)

GMDA Gamida Cell
$6.75 /

-0.07 (-1.03%)

03/09/21 Piper Sandler
Gamida Cell price target lowered to $23 from $25 at Piper Sandler
02/10/21 H.C. Wainwright
Gamida Cell price target raised to $27 from $15 at H.C. Wainwright
02/09/21 Piper Sandler
Gamida Cell price target raised to $25 from $13 at Piper Sandler
12/14/20 Oppenheimer
Gamida Cell price target lowered to $17 from $20 at Oppenheimer
  • 19
    May
GMDA Gamida Cell
$6.75 /

-0.07 (-1.03%)

GMDA Gamida Cell
$6.75 /

-0.07 (-1.03%)

Over a quarter ago
Hot Stocks
Gamida Cell presents efficacy results from Phase 3 omidubicel study » 10:25
03/15/21
03/15
10:25
03/15/21
10:25
GMDA

Gamida Cell

$8.93 /

+0.05 (+0.56%)

Gamida Cell Ltd.…

Gamida Cell Ltd. announced the results of a Phase 3 clinical study of omidubicel presented in an oral session at the Presidential Symposium of the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation. In addition to the Presidential Symposium, the session will be featured in a live panel discussion, "EBMT Talks: Live with the Best Abstracts." This clinical data set, which was also recently presented at the Transplantation & Cellular Therapy Meetings of the American Society of Transplantation and Cellular Therapy and Center for International Blood & Marrow Transplant Research, or the TCT Meetings, was from the international, multi-center, randomized Phase 3 study of omidubicel designed to evaluate the safety and efficacy of omidubicel in patients with high-risk hematologic malignancies undergoing a bone marrow transplant compared to patients who received a standard umbilical cord blood transplant. Gamida Cell previously reported in May 2020 that the study achieved its primary endpoint, showing that omidubicel demonstrated a statistically significant reduction in time to neutrophil engraftment, a measure of how quickly the stem cells a patient receives in a transplant are established and begin to make healthy new cells, and a key milestone in a patient's recovery from a bone marrow transplant. The median time to neutrophil engraftment was 12 days for patients randomized to omidubicel compared to 22 days for the comparator group. All three secondary endpoints demonstrated a statistically significant improvement among patients who were randomized to omidubicel in relation to patients randomized to the comparator group. Platelet engraftment was significantly accelerated with omidubicel, with 55 percent of patients randomized to omidubicel achieving platelet engraftment at day 42, compared to 35 percent for the comparator. The rate of infection was significantly reduced for patients randomized to omidubicel, with the cumulative incidence of first grade 2 or grade 3 bacterial or invasive fungal infection for patients randomized to omidubicel of 37 percent, compared to 57 percent for the comparator. Hospitalization in the first 100 days after transplant was also reduced in patients randomized to omidubicel, with a median number of days alive and out of hospital for patients randomized to omidubicel of 60.5 days, compared to 48.0 days for the comparator. The details of these data were first reported in December 2020.

ShowHide Related Items >><<
GMDA Gamida Cell
$8.93 /

+0.05 (+0.56%)

GMDA Gamida Cell
$8.93 /

+0.05 (+0.56%)

03/09/21 Piper Sandler
Gamida Cell price target lowered to $23 from $25 at Piper Sandler
02/10/21 H.C. Wainwright
Gamida Cell price target raised to $27 from $15 at H.C. Wainwright
02/09/21 Piper Sandler
Gamida Cell price target raised to $25 from $13 at Piper Sandler
12/14/20 Oppenheimer
Gamida Cell price target lowered to $17 from $20 at Oppenheimer
GMDA Gamida Cell
$8.93 /

+0.05 (+0.56%)

  • 19
    May
GMDA Gamida Cell
$8.93 /

+0.05 (+0.56%)

GMDA Gamida Cell
$8.93 /

+0.05 (+0.56%)

Recommendations
Gamida Cell price target lowered to $23 from $25 at Piper Sandler » 12:18
03/09/21
03/09
12:18
03/09/21
12:18
GMDA

Gamida Cell

$8.35 /

+0.19 (+2.33%)

Piper Sandler analyst…

Piper Sandler analyst Edward Tenthoff lowered the firm's price target on Gamida Cell to $23 from $25 and keeps an Overweight rating on the shares. With the Highbridge convertible note, Tenthoff estimates Gamida Cell holds pro forma cash of ~$202M, which will fund operations into the second half of 2022, the analyst tells investors in a research note. Gamida Cell expects to file an IND for GDA-201 and initiate a Phase I/II study in DLBCL and follicular lymphoma in 2H21, the analyst adds.

ShowHide Related Items >><<
GMDA Gamida Cell
$8.35 /

+0.19 (+2.33%)

GMDA Gamida Cell
$8.35 /

+0.19 (+2.33%)

02/10/21 H.C. Wainwright
Gamida Cell price target raised to $27 from $15 at H.C. Wainwright
02/09/21 Piper Sandler
Gamida Cell price target raised to $25 from $13 at Piper Sandler
12/14/20 Oppenheimer
Gamida Cell price target lowered to $17 from $20 at Oppenheimer
12/14/20 Piper Sandler
Gamida Cell delay does not impact peak sales, says Piper Sandler
GMDA Gamida Cell
$8.35 /

+0.19 (+2.33%)

  • 19
    May
GMDA Gamida Cell
$8.35 /

+0.19 (+2.33%)

GMDA Gamida Cell
$8.35 /

+0.19 (+2.33%)

Syndicate
Gamida Cell files to sell 6.33M ordinary shares for holders  16:41
03/01/21
03/01
16:41
03/01/21
16:41
GMDA

Gamida Cell

$9.86 /

+0.46 (+4.89%)

 
ShowHide Related Items >><<
GMDA Gamida Cell
$9.86 /

+0.46 (+4.89%)

GMDA Gamida Cell
$9.86 /

+0.46 (+4.89%)

02/10/21 H.C. Wainwright
Gamida Cell price target raised to $27 from $15 at H.C. Wainwright
02/09/21 Piper Sandler
Gamida Cell price target raised to $25 from $13 at Piper Sandler
12/14/20 Oppenheimer
Gamida Cell price target lowered to $17 from $20 at Oppenheimer
12/14/20 Piper Sandler
Gamida Cell delay does not impact peak sales, says Piper Sandler
GMDA Gamida Cell
$9.86 /

+0.46 (+4.89%)

  • 19
    May
GMDA Gamida Cell
$9.86 /

+0.46 (+4.89%)

GMDA Gamida Cell
$9.86 /

+0.46 (+4.89%)

On The Fly
Fly Intel: Wall Street's top stories for Wednesday » 16:43
02/10/21
02/10
16:43
02/10/21
16:43
AKAM

Akamai

$105.09 /

-12.92 (-10.95%)

, CSCO

Cisco

$47.25 /

-1.19 (-2.46%)

, KO

Coca-Cola

$49.60 /

-0.09 (-0.18%)

, GM

General Motors

$54.87 /

-1.2 (-2.14%)

, TWTR

Twitter

$67.78 /

+7.88 (+13.16%)

, TEVA

Teva

$11.92 /

-0.9 (-7.02%)

, MTCH

Match Group

$171.00 /

+11.97 (+7.53%)

, WMT

Walmart

$144.13 /

-1.68 (-1.15%)

, ORCL

Oracle

$63.27 /

-0.4 (-0.63%)

, FB

Facebook

$271.90 /

+2.36 (+0.88%)

, GMDA

Gamida Cell

$12.41 /

+2.49 (+25.10%)

, LYFT

Lyft

$56.15 /

+2.56 (+4.78%)

, YELP

Yelp

$36.82 /

-1.74 (-4.51%)

, MAT

Mattel

$18.49 /

-0.34 (-1.81%)

The major averages had a…

ShowHide Related Items >><<
YELP Yelp
$36.82 /

-1.74 (-4.51%)

WMT Walmart
$144.13 /

-1.68 (-1.15%)

TWTR Twitter
$67.78 /

+7.88 (+13.16%)

TEVA Teva
$11.92 /

-0.9 (-7.02%)

ORCL Oracle
$63.27 /

-0.4 (-0.63%)

MTCH Match Group
$171.00 /

+11.97 (+7.53%)

MAT Mattel
$18.49 /

-0.34 (-1.81%)

LYFT Lyft
$56.15 /

+2.56 (+4.78%)

KO Coca-Cola
$49.60 /

-0.09 (-0.18%)

GMDA Gamida Cell
$12.41 /

+2.49 (+25.10%)

GM General Motors
$54.87 /

-1.2 (-2.14%)

FB Facebook
$271.90 /

+2.36 (+0.88%)

CSCO Cisco
$47.25 /

-1.19 (-2.46%)

AKAM Akamai
$105.09 /

-12.92 (-10.95%)

AKAM Akamai
$105.09 /

-12.92 (-10.95%)

02/10/21
Fly Intel: Top five analyst downgrades
02/10/21 Craig-Hallum
Akamai downgraded to Hold at Craig-Hallum
02/10/21 Credit Suisse
Akamai price target raised to $115 from $105 at Credit Suisse
02/10/21 Craig-Hallum
Akamai downgraded to Hold from Buy at Craig-Hallum
CSCO Cisco
$47.25 /

-1.19 (-2.46%)

02/11/21 DZ Bank
Cisco upgraded to Buy from Hold at DZ Bank
02/10/21 Evercore ISI
Cisco trends 'slowly but steadily inflecting higher,' says Evercore ISI
02/10/21 Citi
Cisco price target raised to $50 from $45 at Citi
02/10/21 Piper Sandler
Cisco price target raised to $47 from $45 at Piper Sandler
KO Coca-Cola
$49.60 /

-0.09 (-0.18%)

01/19/21 Bernstein
Coca-Cola initiated with an Outperform at Bernstein
01/13/21 HSBC
Coca-Cola price target lowered to $58 from $61 at HSBC
01/07/21
Fly Intel: Top five analyst downgrades
01/07/21 JPMorgan
Coca-Cola downgraded to Neutral on tax risks at JPMorgan
GM General Motors
$54.87 /

-1.2 (-2.14%)

02/11/21 RBC Capital
General Motors price target raised to $67 from $52 at RBC Capital
02/09/21 Barclays
General Motors price target raised to $64 from $56 at Barclays
02/01/21 Wedbush
Nikola upgraded to Neutral from Underperform at Wedbush
01/29/21 Morgan Stanley
General Motors price target raised to $80 from $57 at Morgan Stanley
TWTR Twitter
$67.78 /

+7.88 (+13.16%)

02/10/21 MoffettNathanson
Twitter upgraded to Neutral from Sell at MoffettNathanson
02/10/21 KeyBanc
Twitter price target raised to $80 from $65 at KeyBanc
02/10/21 Oppenheimer
Twitter price target raised to $70 from $58 at Oppenheimer
02/10/21 Wedbush
Twitter price target raised to $56.50 from $47 at Wedbush
TEVA Teva
$11.92 /

-0.9 (-7.02%)

01/26/21 Piper Sandler
Amarin in 'strong position' against Health Net, says Piper Sandler
12/21/20 Gabelli
Teva named 'Best Idea for 2021' at Gabelli
11/27/20 H.C. Wainwright
Corcept Therapeutics price target raised to $32 from $22 at H.C. Wainwright
11/24/20 Oppenheimer
Teva initiated with a Perform at Oppenheimer
MTCH Match Group
$171.00 /

+11.97 (+7.53%)

02/10/21 Wedbush
Match Group price target raised to $150 from $135 at Wedbush
02/05/21 Citi
Match Group price target raised to $175 from $160 at Citi
02/04/21
Fly Intel: Top five analyst upgrades
02/04/21
Match Group upgraded to Overweight on earnings pullback at JPMorgan
WMT Walmart
$144.13 /

-1.68 (-1.15%)

02/09/21 Jefferies
Dollar General well-positioned to mitigate minimum wage headwind, says Jefferies
01/29/21 Jefferies
Carvana, Walmart among 13 additions to Jefferies Franchise Picks list
01/25/21
Fly Intel: Top five analyst downgrades
01/25/21 R5 Capital
R5 Capital downgrades 'operationally challenged' Walmart to Sell
ORCL Oracle
$63.27 /

-0.4 (-0.63%)

01/21/21 Goldman Sachs
Oracle initiated with a Sell at Goldman Sachs
12/18/20
Fly Intel: Top five analyst upgrades
12/18/20 Monness Crespi
Monness Crespi upgrades 'value play' Oracle to Buy with $82 price target
12/18/20 Monness Crespi
Oracle upgraded to Buy from Neutral at Monness Crespi
FB Facebook
$271.90 /

+2.36 (+0.88%)

02/10/21 Tigress Financial
Facebook has 'significant upside' at current levels, says Tigress
02/01/21 Truist
Alphabet price target raised to $2,100 from $2,000 at Truist
01/31/21 Citi
Facebook price target raised to $320 from $315 at Citi
01/28/21 KeyBanc
Facebook price target raised to $360 from $345 at KeyBanc
GMDA Gamida Cell
$12.41 /

+2.49 (+25.10%)

02/10/21 H.C. Wainwright
Gamida Cell price target raised to $27 from $15 at H.C. Wainwright
02/09/21 Piper Sandler
Gamida Cell price target raised to $25 from $13 at Piper Sandler
12/14/20 Oppenheimer
Gamida Cell price target lowered to $17 from $20 at Oppenheimer
12/14/20 Piper Sandler
Gamida Cell delay does not impact peak sales, says Piper Sandler
LYFT Lyft
$56.15 /

+2.56 (+4.78%)

02/11/21 KeyBanc
Uber price target raised to $75 from $63 at KeyBanc
02/11/21 Needham
Needham transfers coverage on Lyft, raises price target $70 from $50
02/10/21 DA Davidson
Lyft price target raised to $66 from $58 at DA Davidson
02/10/21 Jefferies
Lyft price target raised to $75 from $70 at Jefferies
YELP Yelp
$36.82 /

-1.74 (-4.51%)

02/10/21 Truist
Yelp price target raised to $40 from $30 at Truist
02/10/21 Credit Suisse
Yelp price target raised to $41 from $35 at Credit Suisse
02/10/21 Wedbush
Yelp price target raised to $38 from $30 at Wedbush
02/10/21 UBS
Yelp price target raised to $40 from $30 at UBS
MAT Mattel
$18.49 /

-0.34 (-1.81%)

02/10/21 KeyBanc
Mattel price target raised to $22 from $17 at KeyBanc
12/09/20 Citi
Mattel initiated with a Neutral at Citi
11/09/20
Fly Intel: Top five analyst downgrades
11/09/20 Jefferies
Jefferies downgrades Mattel to Hold as stock nears $15 price target
YELP Yelp
$36.82 /

-1.74 (-4.51%)

WMT Walmart
$144.13 /

-1.68 (-1.15%)

TWTR Twitter
$67.78 /

+7.88 (+13.16%)

TEVA Teva
$11.92 /

-0.9 (-7.02%)

ORCL Oracle
$63.27 /

-0.4 (-0.63%)

MTCH Match Group
$171.00 /

+11.97 (+7.53%)

MAT Mattel
$18.49 /

-0.34 (-1.81%)

LYFT Lyft
$56.15 /

+2.56 (+4.78%)

KO Coca-Cola
$49.60 /

-0.09 (-0.18%)

GMDA Gamida Cell
$12.41 /

+2.49 (+25.10%)

GM General Motors
$54.87 /

-1.2 (-2.14%)

FB Facebook
$271.90 /

+2.36 (+0.88%)

CSCO Cisco
$47.25 /

-1.19 (-2.46%)

AKAM Akamai
$105.09 /

-12.92 (-10.95%)

  • 19
    May
YELP Yelp
$36.82 /

-1.74 (-4.51%)

WMT Walmart
$144.13 /

-1.68 (-1.15%)

TWTR Twitter
$67.78 /

+7.88 (+13.16%)

TEVA Teva
$11.92 /

-0.9 (-7.02%)

ORCL Oracle
$63.27 /

-0.4 (-0.63%)

MTCH Match Group
$171.00 /

+11.97 (+7.53%)

LYFT Lyft
$56.15 /

+2.56 (+4.78%)

KO Coca-Cola
$49.60 /

-0.09 (-0.18%)

GM General Motors
$54.87 /

-1.2 (-2.14%)

FB Facebook
$271.90 /

+2.36 (+0.88%)

CSCO Cisco
$47.25 /

-1.19 (-2.46%)

YELP Yelp
$36.82 /

-1.74 (-4.51%)

WMT Walmart
$144.13 /

-1.68 (-1.15%)

TWTR Twitter
$67.78 /

+7.88 (+13.16%)

TEVA Teva
$11.92 /

-0.9 (-7.02%)

ORCL Oracle
$63.27 /

-0.4 (-0.63%)

MTCH Match Group
$171.00 /

+11.97 (+7.53%)

MAT Mattel
$18.49 /

-0.34 (-1.81%)

KO Coca-Cola
$49.60 /

-0.09 (-0.18%)

GMDA Gamida Cell
$12.41 /

+2.49 (+25.10%)

GM General Motors
$54.87 /

-1.2 (-2.14%)

FB Facebook
$271.90 /

+2.36 (+0.88%)

CSCO Cisco
$47.25 /

-1.19 (-2.46%)

AKAM Akamai
$105.09 /

-12.92 (-10.95%)

YELP Yelp
$36.82 /

-1.74 (-4.51%)

WMT Walmart
$144.13 /

-1.68 (-1.15%)

TWTR Twitter
$67.78 /

+7.88 (+13.16%)

TEVA Teva
$11.92 /

-0.9 (-7.02%)

ORCL Oracle
$63.27 /

-0.4 (-0.63%)

MTCH Match Group
$171.00 /

+11.97 (+7.53%)

MAT Mattel
$18.49 /

-0.34 (-1.81%)

LYFT Lyft
$56.15 /

+2.56 (+4.78%)

KO Coca-Cola
$49.60 /

-0.09 (-0.18%)

GMDA Gamida Cell
$12.41 /

+2.49 (+25.10%)

GM General Motors
$54.87 /

-1.2 (-2.14%)

FB Facebook
$271.90 /

+2.36 (+0.88%)

CSCO Cisco
$47.25 /

-1.19 (-2.46%)

AKAM Akamai
$105.09 /

-12.92 (-10.95%)

On The Fly
Fly Intel: Wall Street's top stories at midday » 12:14
02/10/21
02/10
12:14
02/10/21
12:14
KO

Coca-Cola

$49.93 /

+0.24 (+0.48%)

, GM

General Motors

$54.17 /

-1.9 (-3.39%)

, TWTR

Twitter

$64.53 /

+4.63 (+7.73%)

, TEVA

Teva

$11.88 /

-0.945 (-7.37%)

, MTCH

Match Group

$168.32 /

+9.29 (+5.84%)

, GMDA

Gamida Cell

$12.86 /

+2.94 (+29.64%)

, LYFT

Lyft

$56.87 /

+3.28 (+6.12%)

, YELP

Yelp

$35.66 /

-2.9 (-7.52%)

, AKAM

Akamai

$104.21 /

-13.805 (-11.70%)

, CSCO

Cisco

$46.38 /

-2.06 (-4.25%)

, MAT

Mattel

$18.24 /

-0.59 (-3.13%)

, WMT

Walmart

$144.30 /

-1.51 (-1.04%)

, ORCL

Oracle

$63.18 /

-0.49 (-0.77%)

The major averages have…

ShowHide Related Items >><<
YELP Yelp
$35.66 /

-2.9 (-7.52%)

WMT Walmart
$144.30 /

-1.51 (-1.04%)

TWTR Twitter
$64.53 /

+4.63 (+7.73%)

TEVA Teva
$11.88 /

-0.945 (-7.37%)

ORCL Oracle
$63.18 /

-0.49 (-0.77%)

MTCH Match Group
$168.32 /

+9.29 (+5.84%)

MAT Mattel
$18.24 /

-0.59 (-3.13%)

LYFT Lyft
$56.87 /

+3.28 (+6.12%)

KO Coca-Cola
$49.93 /

+0.24 (+0.48%)

GMDA Gamida Cell
$12.86 /

+2.94 (+29.64%)

GM General Motors
$54.17 /

-1.9 (-3.39%)

CSCO Cisco
$46.38 /

-2.06 (-4.25%)

AKAM Akamai
$104.21 /

-13.805 (-11.70%)

KO Coca-Cola
$49.93 /

+0.24 (+0.48%)

01/19/21 Bernstein
Coca-Cola initiated with an Outperform at Bernstein
01/13/21 HSBC
Coca-Cola price target lowered to $58 from $61 at HSBC
01/07/21
Fly Intel: Top five analyst downgrades
01/07/21 JPMorgan
Coca-Cola downgraded to Neutral on tax risks at JPMorgan
GM General Motors
$54.17 /

-1.9 (-3.39%)

02/09/21 Barclays
General Motors price target raised to $64 from $56 at Barclays
02/01/21 Wedbush
Nikola upgraded to Neutral from Underperform at Wedbush
01/29/21 Morgan Stanley
General Motors price target raised to $80 from $57 at Morgan Stanley
01/29/21 Morgan Stanley
Ford downgraded to Underweight on 'ICE liability' at Morgan Stanley
TWTR Twitter
$64.53 /

+4.63 (+7.73%)

02/10/21 KeyBanc
Twitter price target raised to $80 from $65 at KeyBanc
02/10/21 Oppenheimer
Twitter price target raised to $70 from $58 at Oppenheimer
02/10/21 Wedbush
Twitter price target raised to $56.50 from $47 at Wedbush
02/10/21 Truist
Twitter price target raised to $64 from $43 at Truist
TEVA Teva
$11.88 /

-0.945 (-7.37%)

01/26/21 Piper Sandler
Amarin in 'strong position' against Health Net, says Piper Sandler
12/21/20 Gabelli
Teva named 'Best Idea for 2021' at Gabelli
11/27/20 H.C. Wainwright
Corcept Therapeutics price target raised to $32 from $22 at H.C. Wainwright
11/24/20 Oppenheimer
Teva initiated with a Perform at Oppenheimer
MTCH Match Group
$168.32 /

+9.29 (+5.84%)

02/10/21 Wedbush
Match Group price target raised to $150 from $135 at Wedbush
02/05/21 Citi
Match Group price target raised to $175 from $160 at Citi
02/04/21
Fly Intel: Top five analyst upgrades
02/04/21
Match Group upgraded to Overweight on earnings pullback at JPMorgan
GMDA Gamida Cell
$12.86 /

+2.94 (+29.64%)

02/10/21 H.C. Wainwright
Gamida Cell price target raised to $27 from $15 at H.C. Wainwright
02/09/21 Piper Sandler
Gamida Cell price target raised to $25 from $13 at Piper Sandler
12/14/20 Oppenheimer
Gamida Cell price target lowered to $17 from $20 at Oppenheimer
12/14/20 Piper Sandler
Gamida Cell delay does not impact peak sales, says Piper Sandler
LYFT Lyft
$56.87 /

+3.28 (+6.12%)

02/10/21 DA Davidson
Lyft price target raised to $66 from $58 at DA Davidson
02/10/21 Jefferies
Lyft price target raised to $75 from $70 at Jefferies
02/10/21 KeyBanc
Lyft price target raised to $72 from $57 at KeyBanc
02/10/21 Credit Suisse
Lyft price target raised to $74 from $66 at Credit Suisse
YELP Yelp
$35.66 /

-2.9 (-7.52%)

02/10/21 Truist
Yelp price target raised to $40 from $30 at Truist
02/10/21 Credit Suisse
Yelp price target raised to $41 from $35 at Credit Suisse
02/10/21 Wedbush
Yelp price target raised to $38 from $30 at Wedbush
02/10/21 UBS
Yelp price target raised to $40 from $30 at UBS
AKAM Akamai
$104.21 /

-13.805 (-11.70%)

02/10/21
Fly Intel: Top five analyst downgrades
02/10/21 Craig-Hallum
Akamai downgraded to Hold at Craig-Hallum
02/10/21 Credit Suisse
Akamai price target raised to $115 from $105 at Credit Suisse
02/10/21 Craig-Hallum
Akamai downgraded to Hold from Buy at Craig-Hallum
CSCO Cisco
$46.38 /

-2.06 (-4.25%)

02/10/21 Evercore ISI
Cisco trends 'slowly but steadily inflecting higher,' says Evercore ISI
02/10/21 Citi
Cisco price target raised to $50 from $45 at Citi
02/10/21 Piper Sandler
Cisco price target raised to $47 from $45 at Piper Sandler
01/25/21 JPMorgan
Cisco price target raised to $50 from $44 at JPMorgan
MAT Mattel
$18.24 /

-0.59 (-3.13%)

02/10/21 KeyBanc
Mattel price target raised to $22 from $17 at KeyBanc
12/09/20 Citi
Mattel initiated with a Neutral at Citi
11/09/20
Fly Intel: Top five analyst downgrades
11/09/20 Jefferies
Jefferies downgrades Mattel to Hold as stock nears $15 price target
WMT Walmart
$144.30 /

-1.51 (-1.04%)

02/09/21 Jefferies
Dollar General well-positioned to mitigate minimum wage headwind, says Jefferies
01/29/21 Jefferies
Carvana, Walmart among 13 additions to Jefferies Franchise Picks list
01/25/21
Fly Intel: Top five analyst downgrades
01/25/21 R5 Capital
R5 Capital downgrades 'operationally challenged' Walmart to Sell
ORCL Oracle
$63.18 /

-0.49 (-0.77%)

01/21/21 Goldman Sachs
Oracle initiated with a Sell at Goldman Sachs
12/18/20
Fly Intel: Top five analyst upgrades
12/18/20 Monness Crespi
Monness Crespi upgrades 'value play' Oracle to Buy with $82 price target
12/18/20 Monness Crespi
Oracle upgraded to Buy from Neutral at Monness Crespi
YELP Yelp
$35.66 /

-2.9 (-7.52%)

WMT Walmart
$144.30 /

-1.51 (-1.04%)

TWTR Twitter
$64.53 /

+4.63 (+7.73%)

TEVA Teva
$11.88 /

-0.945 (-7.37%)

ORCL Oracle
$63.18 /

-0.49 (-0.77%)

MTCH Match Group
$168.32 /

+9.29 (+5.84%)

MAT Mattel
$18.24 /

-0.59 (-3.13%)

LYFT Lyft
$56.87 /

+3.28 (+6.12%)

KO Coca-Cola
$49.93 /

+0.24 (+0.48%)

GMDA Gamida Cell
$12.86 /

+2.94 (+29.64%)

GM General Motors
$54.17 /

-1.9 (-3.39%)

CSCO Cisco
$46.38 /

-2.06 (-4.25%)

AKAM Akamai
$104.21 /

-13.805 (-11.70%)

  • 19
    May
YELP Yelp
$35.66 /

-2.9 (-7.52%)

WMT Walmart
$144.30 /

-1.51 (-1.04%)

TWTR Twitter
$64.53 /

+4.63 (+7.73%)

TEVA Teva
$11.88 /

-0.945 (-7.37%)

ORCL Oracle
$63.18 /

-0.49 (-0.77%)

MTCH Match Group
$168.32 /

+9.29 (+5.84%)

LYFT Lyft
$56.87 /

+3.28 (+6.12%)

KO Coca-Cola
$49.93 /

+0.24 (+0.48%)

GM General Motors
$54.17 /

-1.9 (-3.39%)

CSCO Cisco
$46.38 /

-2.06 (-4.25%)

YELP Yelp
$35.66 /

-2.9 (-7.52%)

WMT Walmart
$144.30 /

-1.51 (-1.04%)

TWTR Twitter
$64.53 /

+4.63 (+7.73%)

TEVA Teva
$11.88 /

-0.945 (-7.37%)

ORCL Oracle
$63.18 /

-0.49 (-0.77%)

MTCH Match Group
$168.32 /

+9.29 (+5.84%)

MAT Mattel
$18.24 /

-0.59 (-3.13%)

LYFT Lyft
$56.87 /

+3.28 (+6.12%)

KO Coca-Cola
$49.93 /

+0.24 (+0.48%)

GMDA Gamida Cell
$12.86 /

+2.94 (+29.64%)

GM General Motors
$54.17 /

-1.9 (-3.39%)

CSCO Cisco
$46.38 /

-2.06 (-4.25%)

AKAM Akamai
$104.21 /

-13.805 (-11.70%)

YELP Yelp
$35.66 /

-2.9 (-7.52%)

WMT Walmart
$144.30 /

-1.51 (-1.04%)

TWTR Twitter
$64.53 /

+4.63 (+7.73%)

TEVA Teva
$11.88 /

-0.945 (-7.37%)

ORCL Oracle
$63.18 /

-0.49 (-0.77%)

MTCH Match Group
$168.32 /

+9.29 (+5.84%)

MAT Mattel
$18.24 /

-0.59 (-3.13%)

LYFT Lyft
$56.87 /

+3.28 (+6.12%)

KO Coca-Cola
$49.93 /

+0.24 (+0.48%)

GMDA Gamida Cell
$12.86 /

+2.94 (+29.64%)

GM General Motors
$54.17 /

-1.9 (-3.39%)

CSCO Cisco
$46.38 /

-2.06 (-4.25%)

AKAM Akamai
$104.21 /

-13.805 (-11.70%)

On The Fly
Fly Intel: Pre-market Movers » 08:57
02/10/21
02/10
08:57
02/10/21
08:57
GMDA

Gamida Cell

$9.92 /

-0.19 (-1.88%)

, ACIC

Atlas Crest Investment Corp.

$11.15 /

-0.1 (-0.89%)

, CMLF

CM Life Sciences

$15.50 /

+1.325 (+9.35%)

, KO

Coca-Cola

$49.70 /

-0.23 (-0.46%)

, GM

General Motors

$56.07 /

-0.82 (-1.44%)

, IQV

Iqvia

$184.05 /

-2.81 (-1.50%)

, LYFT

Lyft

$53.59 /

+0.16 (+0.30%)

, CSCO

Cisco

$48.44 /

-0.49 (-1.00%)

, AKAM

Akamai

$118.01 /

+0.73 (+0.62%)

, SAVA

Cassava Sciences

$57.40 /

-3.16 (-5.22%)

, ENLV

Enlivex Therapeutics

$23.90 /

+0.85 (+3.69%)

, XONE

ExOne

$64.40 /

+9.9 (+18.17%)

, ACHR

Archer

$0.00 /

+ (+0.00%)

, UAL

United Airlines

$43.32 /

-1.03 (-2.32%)

Check out this morning's…

ShowHide Related Items >><<
XONE ExOne
$64.40 /

+9.9 (+18.17%)

UAL United Airlines
$43.32 /

-1.03 (-2.32%)

SAVA Cassava Sciences
$57.40 /

-3.16 (-5.22%)

LYFT Lyft
$53.59 /

+0.16 (+0.30%)

KO Coca-Cola
$49.70 /

-0.23 (-0.46%)

IQV Iqvia
$184.05 /

-2.81 (-1.50%)

GMDA Gamida Cell
$9.92 /

-0.19 (-1.88%)

GM General Motors
$56.07 /

-0.82 (-1.44%)

ENLV Enlivex Therapeutics
$23.90 /

+0.85 (+3.69%)

CSCO Cisco
$48.44 /

-0.49 (-1.00%)

CMLF CM Life Sciences
$15.50 /

+1.325 (+9.35%)

AKAM Akamai
$118.01 /

+0.73 (+0.62%)

ACIC Atlas Crest Investment Corp.
$11.15 /

-0.1 (-0.89%)

GMDA Gamida Cell
$9.92 /

-0.19 (-1.88%)

02/10/21 H.C. Wainwright
Gamida Cell price target raised to $27 from $15 at H.C. Wainwright
02/09/21 Piper Sandler
Gamida Cell price target raised to $25 from $13 at Piper Sandler
12/14/20 Oppenheimer
Gamida Cell price target lowered to $17 from $20 at Oppenheimer
12/14/20 Piper Sandler
Gamida Cell delay does not impact peak sales, says Piper Sandler
ACIC Atlas Crest Investment Corp.
$11.15 /

-0.1 (-0.89%)

CMLF CM Life Sciences
$15.50 /

+1.325 (+9.35%)

KO Coca-Cola
$49.70 /

-0.23 (-0.46%)

01/19/21 Bernstein
Coca-Cola initiated with an Outperform at Bernstein
01/13/21 HSBC
Coca-Cola price target lowered to $58 from $61 at HSBC
01/07/21
Fly Intel: Top five analyst downgrades
01/07/21 JPMorgan
Coca-Cola downgraded to Neutral on tax risks at JPMorgan
GM General Motors
$56.07 /

-0.82 (-1.44%)

02/09/21 Barclays
General Motors price target raised to $64 from $56 at Barclays
02/01/21 Wedbush
Nikola upgraded to Neutral from Underperform at Wedbush
01/29/21 Morgan Stanley
General Motors price target raised to $80 from $57 at Morgan Stanley
01/29/21 Morgan Stanley
Ford downgraded to Underweight on 'ICE liability' at Morgan Stanley
IQV Iqvia
$184.05 /

-2.81 (-1.50%)

12/18/20 Mizuho
Iqvia price target raised to $200 from $190 at Mizuho
10/22/20 Deutsche Bank
Iqvia price target raised to $196 from $180 at Deutsche Bank
10/21/20 UBS
Iqvia price target raised to $224 from $204 at UBS
10/21/20 Morgan Stanley
Iqvia price target raised to $195 from $182 at Morgan Stanley
LYFT Lyft
$53.59 /

+0.16 (+0.30%)

02/10/21 Credit Suisse
Lyft price target raised to $74 from $66 at Credit Suisse
02/10/21 MKM Partners
Lyft price target raised to $58 from $37 at MKM Partners
02/10/21 Wedbush
Lyft price target raised to $72 from $53 at Wedbush
02/10/21 Morgan Stanley
Lyft price target raised to $60 from $55 at Morgan Stanley
CSCO Cisco
$48.44 /

-0.49 (-1.00%)

02/10/21 Evercore ISI
Cisco trends 'slowly but steadily inflecting higher,' says Evercore ISI
02/10/21 Citi
Cisco price target raised to $50 from $45 at Citi
02/10/21 Piper Sandler
Cisco price target raised to $47 from $45 at Piper Sandler
01/25/21 JPMorgan
Cisco price target raised to $50 from $44 at JPMorgan
AKAM Akamai
$118.01 /

+0.73 (+0.62%)

02/10/21 Credit Suisse
Akamai price target raised to $115 from $105 at Credit Suisse
02/10/21 Craig-Hallum
Akamai downgraded to Hold from Buy at Craig-Hallum
02/10/21 JPMorgan
Akamai downgraded to Neutral from Overweight at JPMorgan
11/12/20 Piper Sandler
Akamai price target lowered to $120 from $125 at Piper Sandler
SAVA Cassava Sciences
$57.40 /

-3.16 (-5.22%)

02/02/21 Cantor Fitzgerald
Cantor says Cassava analyses 'encouraging,' but should be viewed with caution
10/22/20 Cantor Fitzgerald
Cassava Sciences initiated with an Overweight at Cantor Fitzgerald
09/23/20 H.C. Wainwright
Cassava Sciences upgraded to Buy from Neutral at H.C. Wainwright
09/14/20 Maxim
Cassava upgraded to Buy at Maxim after second analysis of AD drug data
ENLV Enlivex Therapeutics
$23.90 /

+0.85 (+3.69%)

03/10/20 H.C. Wainwright
Enlivex Therapeutics price target raised to $22 from $20 at H.C. Wainwright
XONE ExOne
$64.40 /

+9.9 (+18.17%)

02/09/21 B. Riley
ExOne price target raised to $44 from $10.50 at B. Riley Securities
02/08/21 Canaccord
ExOne price target raised to $59 from $18 at Canaccord
01/29/21 Alliance Global Partners
ExOne upgraded to Buy from Neutral at Alliance Global Partners
01/19/21 Stifel
ExOne initiated with a Buy at Stifel
ACHR Archer
$0.00 /

+ (+0.00%)

UAL United Airlines
$43.32 /

-1.03 (-2.32%)

02/10/21 JPMorgan
JPMorgan sees less than 15% chance of pre-flight COVID-19 testing
01/14/21 Susquehanna
United Airlines price target raised to $40 from $38 at Susquehanna
01/11/21 Cowen
United Airlines upgraded to Outperform from Market Perform at Cowen
01/08/21
Fly Intel: Top five analyst downgrades
XONE ExOne
$64.40 /

+9.9 (+18.17%)

UAL United Airlines
$43.32 /

-1.03 (-2.32%)

SAVA Cassava Sciences
$57.40 /

-3.16 (-5.22%)

LYFT Lyft
$53.59 /

+0.16 (+0.30%)

KO Coca-Cola
$49.70 /

-0.23 (-0.46%)

IQV Iqvia
$184.05 /

-2.81 (-1.50%)

GMDA Gamida Cell
$9.92 /

-0.19 (-1.88%)

GM General Motors
$56.07 /

-0.82 (-1.44%)

CSCO Cisco
$48.44 /

-0.49 (-1.00%)

AKAM Akamai
$118.01 /

+0.73 (+0.62%)

  • 10
    Feb
  • 10
    Feb
  • 13
    Nov
  • 19
    May
  • 22
    Apr
UAL United Airlines
$43.32 /

-1.03 (-2.32%)

LYFT Lyft
$53.59 /

+0.16 (+0.30%)

KO Coca-Cola
$49.70 /

-0.23 (-0.46%)

GM General Motors
$56.07 /

-0.82 (-1.44%)

CSCO Cisco
$48.44 /

-0.49 (-1.00%)

UAL United Airlines
$43.32 /

-1.03 (-2.32%)

SAVA Cassava Sciences
$57.40 /

-3.16 (-5.22%)

LYFT Lyft
$53.59 /

+0.16 (+0.30%)

KO Coca-Cola
$49.70 /

-0.23 (-0.46%)

IQV Iqvia
$184.05 /

-2.81 (-1.50%)

GMDA Gamida Cell
$9.92 /

-0.19 (-1.88%)

GM General Motors
$56.07 /

-0.82 (-1.44%)

CSCO Cisco
$48.44 /

-0.49 (-1.00%)

AKAM Akamai
$118.01 /

+0.73 (+0.62%)

UAL United Airlines
$43.32 /

-1.03 (-2.32%)

SAVA Cassava Sciences
$57.40 /

-3.16 (-5.22%)

LYFT Lyft
$53.59 /

+0.16 (+0.30%)

KO Coca-Cola
$49.70 /

-0.23 (-0.46%)

GMDA Gamida Cell
$9.92 /

-0.19 (-1.88%)

GM General Motors
$56.07 /

-0.82 (-1.44%)

ENLV Enlivex Therapeutics
$23.90 /

+0.85 (+3.69%)

CSCO Cisco
$48.44 /

-0.49 (-1.00%)

AKAM Akamai
$118.01 /

+0.73 (+0.62%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.